The patients we included in our study were relatively young, predominantly non‐smoking female, and primarily adenocarcinoma histology, which is a population with a high probability of harboring EGFR mutations and the dominant population for EGFR‐TKI treatment. This evidence concerns the gene EGFR and adenocarcinoma.